Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Diabetes Mellitus ( Type 1 and Type 2), Hypertension
Interventions: Guide My Care Tool; Other
Lead sponsor: Fitbit LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions: Laboratory clotting studies; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 0 Hours to 2 Hours
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hypertension, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Comorbidities and Coexisting Conditions
Interventions: Improved Community Health Volunteer (CHV) program; Other
Lead sponsor: International Rescue Committee; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: Glucose Variability Observation; Procedure
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Closed-Loop Control System, Sensor-Augmented Pump (SAP); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 69 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Santa Barbara, California • Stanford, California • Charlottesville, Virginia

Conditions: Type1 Diabetes Mellitus
Interventions: Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Stanford, California • New York, New York • Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. C sensor algorithm applied retrospectively to raw sensor data., Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter. Zeus sensor algorithm applied retrospectively to raw sensor data., Acetominophen; Device · Drug
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 6
States / cities: Escondido, California • Santa Barbara, California • Walnut Creek, California + 3 more

Conditions: Type 1 Diabetes
Interventions: HIGH error, NO error, LOW error; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Intervention to increase diabetes technology uptake; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 12 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Duarte, California • Baltimore, Maryland • New York, New York + 4 more

Conditions: Diabetes Mellitus, Type I
Interventions: Not listed
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 10 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 5
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 2 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Allogeneic Cultured Islet Cells (human); Encapsulated; Biological
Lead sponsor: Novocell; Industry
Eligibility: 20 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes
Interventions: Sitagliptin, Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: "MyPlan" - Individualized Planned Eating Pattern; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Cincinnati, Ohio

Conditions: Diabetes
Interventions: One-time blood (up to 100 ml) will be drawn and the amount of blood drawn is based on weight. Saliva and urine will be collected during the blood draw visit.; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes Mellitus, Type 1, Overweight and Obesity
Interventions: Hypocaloric, low carbohydrate diet, Hypocaloric, moderate low fat diet, Mediterranean diet, no caloric restriction; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 19 Years to 30 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Diabetes Assistant (DiAs) with Closed-Loop; Device
Lead sponsor: University of Virginia; Other
Eligibility: 5 Years to 9 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes (T1D)
Interventions: DailyDose; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 3 more

Conditions: Type 1 Diabetes
Interventions: Virtual home intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 19 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Type 1 Diabetes
Interventions: Insulin; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetes, Type 1 Diabetes
Interventions: Alpha 1-Antitrypsin (AAT, Aralast NP); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Heart rate informed SSM+HMM; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Care COMPASS Study

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s

Community Models for Hypertension and Diabetes Care for Refugees

Imaging Inflammation in Autoimmune Diabetes

Biobehavioral Mechanisms of Glucose Variability

Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults

Effect of Gain on Closed-Loop Insulin

BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes

"MyPlan" - Individualized Planned Eating Patterns for Adolescents With Type 1 Diabetes

Circulating Biomarkers in the Development of Type 1 Diabetes

ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform

App-Based Certified Diabetes Education Therapy (AB-CDE)

Virtual Physical Activity for Type 1 Diabetes

Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker